MedTrace Logo

Treatment of Multiple Attacks of Acute Migraine (0462-025)

NCT00899379 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 473

Last updated 2022-02-03

Study results available
· View outcomes & findings →

Summary

A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.

Conditions

  • Migraine Headache

Interventions

DRUG

rizatriptan benzoate

Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache

DRUG

Comparator: Placebo

Placebo to Rizatriptan, Oral Tablet

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-04-30
Primary Completion
1996-01-31
Completion
1996-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00899379 on ClinicalTrials.gov